AlumisALMS +5.52%12 9-Day RSI is 75.90 as of Jun. 28, 2026. GuruFocus rates ALMS with a GF Score™ of 12/100. The stock has 4 warning signs investors should review. Among 1,423 Biotechnology companies, Alumis ranks worse than 93.18% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-06-28), Alumis's 9-Day RSI is 75.90.
The industry rank for Alumis's 9-Day RSI or its related term are showing as below:
ALMS's 9-Day RSI is ranked worse than 93.18% of 1423
companies
in the Biotechnology industry
Industry Median: 45.82
vs ALMS: 75.90
Alumis (NAS:ALMS) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Alumis 9-Day RSI Related Terms
ALMS vs SLNO, ARQT, IRON: 9-Day RSI Comparison
For the Biotechnology subindustry, Alumis's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alumis 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alumis's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Alumis's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alumis (ALMS) has a 9-Day RSI of 75.90 as of Jun. 28, 2026. According to the industry distribution chart, Alumis ranks #1326 out of 1423 companies in the Biotechnology industry, placing it in the top 93.2%.
Is Alumis' 9-Day RSI too high?
Alumis' current 9-Day RSI is 75.90. The Biotechnology industry median 9-Day RSI is 45.82. Alumis' value of 75.90 is 65.6% above this industry median. Based on the distribution chart, Alumis ranks #1326 out of 1423 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Alumis has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Alumis' 9-Day RSI compare to SLNO and ARQT?
According to the Biotechnology industry distribution chart, Alumis ranks #1326 out of 1423 companies for 9-Day RSI. This places Alumis in the lower half of its industry. The industry median 9-Day RSI is 45.82. Alumis' value of 75.90 is 65.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 45.82, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alumis's current 9-Day RSI of 75.90 is 65.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 45.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alumis's current 9-Day RSI is 75.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alumis stock overvalued right now?
Alumis (ALMS) has a current 9-Day RSI of 75.90. The current 9-Day RSI is 75.90 and 65.6% above the Biotechnology industry median of 45.82. Alumis' overall GF Score™ is 12/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Alumis (ALMS), the current 9-Day RSI is 75.90 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
12GF Score
Get the complete analysis for ALMS
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALMS has been successfully added to your 